San Francisco, CA, May 16, 2019 (GLOBE NEWSWIRE) -- Honglan Wang is pleased to announce her new business as an independent consultant with a focus in the biotechnology field.
Honglan is an experienced biotechnology industry team leader with strong scientific background. Currently she is working with Lingyi Bioechnology, a newly launched company dedicates to research & development, manufacturing, and commercialization of medical diagnostic products. Honglan has provided them with services in technological strategies, R&D, and project management. Lingyi is showing great promise and is on track to strengthen.
Ms. Wang also has solid drug discovery knowledge. She used to work as a senior scientist and team leader in Myokardia, a company is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Honglan was hired to assemble and manage a talented team of technically diverse scientists, who were brought together as a focused team to work flawlessly together to generate data needed to make high-level decisions. She had also taken the lead on several projects that have moved program forward.
Honglan has a Ph.D. degree of cardiovascular pharmacology and had her postdoctoral training in cardiovascular physiology and pharmacology. Her scientific knowledge and experiences include cell pharmacology/biology, ex vivo pharmacology, and in vivo pharmacology. She has many years of experience in studying and managing transgenic, surgical, and drug induced disease animal models. She is comfortable operating simultaneously as team leader and technical contributor. She has excellent presentation, communication, interpersonal, and team building skills. She has numerous awards, scientific journal publications, conference presentations.